Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
|
| Abstract |
The accurate diagnosis of differentiated thyroid tumors is very important for clinical management of patients. The histopathological distinction between some types of differentiated thyroid tumors can be very difficult even for experienced pathologists. We used immunohistochemical markers from published data obtained from DNA expression profiling, tissue microarray analysis, and immunohistochemistry to analyze a series of 157 thyroid tumors and 5 normal thyroids. These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001). A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma. Because individual tumors may not express some of these markers, the use of a panel of antibodies is recommended. These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).
|
|---|---|
| Authors | Nobuki Nakamura, Lori A Erickson, Long Jin, Sabine Kajita, Heyu Zhang, Xiang Qian, Kandelaria Rumilla, Ricardo V Lloyd |
| Journal | Endocrine pathology (Endocr Pathol) Vol. 17 Issue 3 Pg. 213-23 ( 2006) ISSN: 1046-3976 [Print] United States |
| PMID | 17308358 (Publication Type: Historical Article, Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!